Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Monitoring Telotristat Ethyl Inhibition of Tryptophan Hydroxylase (TPH) in Neuroendocrine Tumors Using ?-[11C]Methyl-L-tryptophan (AMT)-PET

NCT03453489 is registered in ClinicalTrials.gov with Barbara Ann Karmanos Cancer Institute as lead sponsor.

NCT NCT03453489
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03453489 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Monitoring Telotristat Ethyl Inhibition of Tryptophan Hydroxylase (TPH) in Neuroendocrine Tumors Using ?-[11C]Methyl-L-tryptophan (AMT)-PET
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Phase
Phase 2
Overall status
Completed
Start date
June 20, 2018
Completion date
October 15, 2020
Enrollment
4 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoid syndrome, metastatic nonfunctional well differentiated neuroendocrine neoplasm